Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.
Rhesus macaques were immunized with a combination vaccine regimen consisting of adenovirus type 5 host range mutant-simian immunodeficiency virus envelope (Ad5hr-SIVenv) recombinant priming and boosting with native SIV gp120. Upon intravaginal challenge with SIVmac251, both persistently and transiently viremic animals were observed (S. L. Buge, E. Richardson, S. Alipanah, P. Markham, S. Cheng, N. Kalyan, C. J. Miller, M. Lubeck, S. Udem, J. Eldridge, and M. Robert-Guroff, J. Virol. 71:8531-8541, 1997). Long-term follow-up of the persistently viremic immunized macaques, which displayed significantly reduced viral burdens during the first 18 weeks postchallenge compared to controls, has now shown that one of four became a slow progressor, clearing virus from plasma and remaining asymptomatic with stable CD4 counts for 134 weeks postchallenge. Reboosting of the transiently viremic macaques did not reactivate latent virus. Rechallenge with two sequential SIVmac251 intravaginal exposures again resulted in partial protection of one of two immunized macaques, manifested by viral clearance and stable CD4 counts. No single immune parameter was associated with partial protection. Development of a strong antibody response capable of neutralizing a primary SIVmac251 isolate together with SIV-specific cytotoxic T lymphocytes were implicated, while CD8(+) T-cell antiviral activity and mucosal immune responses were not associated with delayed disease progression. Our data show that even a third immunization with the same Ad5hr-SIVenv recombinant can elicit significant immune responses to the inserted gene product, suggesting that preexisting Ad antibodies may not preclude effective immunization. Further, the partial protection against a virulent, pathogenic SIV challenge observed in two of six macaques immunized with a vaccine regimen based solely on the viral envelope indicates that this vectored-vaccine approach has promise and that multicomponent vaccines based in the same system merit further investigation.
Buge
S L
SL
Basic Research Laboratory, National Cancer Institute, Bethesda, Maryland 20892, USA.
Murty
L
L
Arora
K
K
Kalyanaraman
V S
VS
Markham
P D
PD
Richardson
E S
ES
Aldrich
K
K
Patterson
L J
LJ
Miller
C J
CJ
Cheng
S M
SM
Robert-Guroff
M
M
D000260:Adenoviruses, Human / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D002461:Cell Line, Transformed; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005822:Genetic Vectors / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal / Q000276:immunology; D008253:Macaca mulatta; D008562:Membrane Glycoproteins; D011993:Recombinant Fusion Proteins / Q000276:immunology; D018449:SAIDS Vaccines / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000254:growth & development / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology*; D014621:Vagina / Q000276:immunology / Q000821:virology; D014759:Viral Envelope Proteins; D014766:Viremia
D000914:Antibodies, Viral; D015699:HIV Envelope Protein gp120; D008562:Membrane Glycoproteins; D011993:Recombinant Fusion Proteins; D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; C069623:gp120 protein, Simian immunodeficiency virus